News headlines about Oasmia Pharmaceutical AB (NASDAQ:OASM) have trended somewhat negative this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oasmia Pharmaceutical AB earned a daily sentiment score of -0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.6879847516605 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Oasmia Pharmaceutical AB (NASDAQ:OASM) traded up 3.70% during mid-day trading on Friday, hitting $1.12. The stock had a trading volume of 62,285 shares. Oasmia Pharmaceutical AB has a 52-week low of $0.94 and a 52-week high of $3.70. The firm has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.04. The firm’s market cap is $64.54 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB (publ) develops, produces, markets, and sells drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer.

Insider Buying and Selling by Quarter for Oasmia Pharmaceutical AB (NASDAQ:OASM)

Receive News & Stock Ratings for Oasmia Pharmaceutical AB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oasmia Pharmaceutical AB and related stocks with our FREE daily email newsletter.